3E05003Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach

  • Billable / Specific Code
ICD-10-PCS 3E05003
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

3E05003 is a billable ICD-10-PCS procedure code for Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
3E05003
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach
Short Description
Introduction of Low dose IL-2 into Periph Art, Open Approach
Parent Code

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1Section3Administration
2Body SystemEPhysiological Systems and Anatomical Regions
3Operation0Introduction
4BodySystem/Region5Peripheral Artery
5Approach0Open
6Substance0Antineoplastic
7Qualifier3Low-dose Interleukin-2

In the ICD-10-PCS Alphabetic Index

These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:

Anatomy or device term that leads here
Anatomy or device term that leads here
Anatomy or device term that leads here
Immunotherapy, antineoplastic, Interferon
Anatomy or device term that leads here
Anatomy or device term that leads here
Immunotherapy, antineoplastic, Proleukin, low-dose
Anatomy or device term that leads here
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Serum
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Toxoid
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Hormone
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Vaccine
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Hypnotics
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Sedatives
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Analgesics
Leads to this code's table
Introduction of substance in or on, Artery, Peripheral, Vasopressor
Leads to this code's table

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Convert to ICD-9-PCS

Closest ICD-9-PCS equivalents for this code under the General Equivalence Mappings.

99.28
Injection or infusion of biological response modifier [BRM] as an antineoplastic agent
Approximate match.

Similar Procedure Codes

Questions About 3E05003

Is 3E05003 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in 3E05003 mean?

The code breaks down character by character: the 1st character 3 is the Section (Administration); the 2nd character E is the Body System (Physiological Systems and Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 5 is the BodySystem/Region (Peripheral Artery); the 5th character 0 is the Approach (Open); the 6th character 0 is the Substance (Antineoplastic); the 7th character 3 is the Qualifier (Low-dose Interleukin-2).

What is the ICD-9-PCS equivalent of 3E05003?

Under the General Equivalence Mappings, Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach crosswalks to ICD-9-PCS 99.28 (Injection or infusion of biological response modifier [BRM] as an antineoplastic agent). The mapping is approximate, so confirm it fits the documentation.